Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Translational Phase 1/2 Dose-Escalation and Expansion Study to Determine Safety, Tolerability, and Recommended Phase 2 Dose of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

NCT05278975 is registered in ClinicalTrials.gov with RS Oncology LLC as lead sponsor.

NCT NCT05278975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05278975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Translational Phase 1/2 Dose-Escalation and Expansion Study to Determine Safety, Tolerability, and Recommended Phase 2 Dose of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
Lead sponsor
RS Oncology LLC
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2022
Completion date
May 7, 2026
Enrollment
50 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

malignant pleural effusion, malignant pleural mesothelioma, mesothelioma, mesothelioma; lung, mesotheliomas pleural, pleural effusion, malignant